On July 13, 2026, federal regulators cleared a weekly shot to start treatment for early Alzheimer's disease. Leqembi Iqlik, the brand name for subcutaneous lecanemab-irmb, can begin care from day one, Eisai and Biogen reported in the FDA approval notice. Read the headline as easier access with the same strict safety rules. It does not mean a stronger effect, a cure, or care without brain scans and doctor visits.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Apply through Multivu’s official page — Use this page to review requirements and apply directly.
- Read the official notice from Optum — Use this primary source to verify the official announcement.
Table of Contents
- What actually changed in July 2026?
- Who can start the weekly shot?
- What safety checks stay with home use?
- What should caregivers plan week to week?
What actually changed in July 2026?
Before this action, Leqembi Iqlik was only for maintenance, as Drugs.com history notes. That older use was 360 mg weekly after 18 months of prior treatment.
The new starter is 500 mg each week, given as two back-to-back 250-mg shots. Optum described this schedule and the new 250 mg/1.25 mL autoinjector in its drug-approval summary.
Who can start the weekly shot?
The drug is only for early disease, not moderate or advanced dementia. The Alzheimer's Association limits use to adults with mild impairment or mild dementia due to Alzheimer's with high amyloid, in its Leqembi treatment page.
Proof must come from a PET scan or spinal-fluid test. Gather these three checks before you call the clinic: If any item is missing, the doctor will order testing first. Do not stop current supervision or support while you wait.
- diagnosis of mild cognitive impairment or mild dementia linked to Alzheimer's
- PET or spinal-fluid result showing elevated amyloid
- recent brain MRI and a plan for repeat scans
What safety checks stay with home use?
The FDA label carries a boxed warning for amyloid-related imaging abnormalities. Those events include ARIA-E swelling and ARIA-H tiny bleeds, with baseline and repeat MRIs required, stated in the FDA label via FDA.report.
Home shots do not remove scan visits. Keep every MRI date, bring a drug list, and call promptly about new changes. Ask what the clinic wants reported between visits.
What should caregivers plan week to week?
Eisai said the starter became available in late August 2026 through specialty pharmacy. It is built for home use by patients or care partners. Eisai and Biogen reported AAIC 2026 London data showing similar benefit and safety for the shot versus the vein drip.
Drugs.com explains the drug slows decline by about 27% over 18 months but does not stop, reverse, or cure disease. Plan for continued help with meals, rides, bills, and watchful hours. Keep MRI and safety visits on the calendar before the first home dose.
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: How Primary Care Patients Can Compare Testing Options
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: How Primary Care Patients Can Compare Testing Options
- How 2026 Tau Imaging News May Affect Alzheimer’s Workups: How Primary Care Patients Can Compare Testing Options
